Post hoc analysis of the SYNERGY trial in overactive bladder: benefit of solifenacin plus mirabegron matched independent (additive) drug action, not synergy. With S5+M50, 50.7% had zero urgency incontinence vs 62.4% predicted; no endpoint exceeded additive expectations.
Secondary analysis
Chen et al. Quantitative Assessment of Additive Effects of Mirabegron and Solifenacin in Overactive Bladder: Re-analysis of SYNERGY Study